For the roughly 300,000 Americans living with spinal cord injury, the gap between laboratory promise and real-world assistive technology remains frustratingly wide. A prospective longitudinal study assessing the Atalante self-balancing exoskeleton closes some of that gap by systematically measuring not just whether the device works mechanically, but whether it is safe, usable, and acceptable to the people who depend on it — a trifecta rarely evaluated together in this population.
The trial enrolled 13 adults with chronic complete thoracic spinal cord injury classified at ASIA Impairment Scale grade A, with neurological levels between T6 and T12 — meaning zero motor or sensory function below the lesion. Over six weeks, 11 participants completed 60 supervised sessions each involving 40 meters of exoskeleton-assisted walking. The study tracked three parallel outcome domains: medical adverse events and near-falls for safety; donning/doffing times, assistance levels, and cumulative walking exposure for techno-functional usability; and session-by-session visual analogue scale ratings of comfort and perceived safety for patient acceptability. Physiological load was assessed via exoskeleton-assisted six-minute walk tests across the program duration.
This research sits at an important inflection point in rehabilitation engineering. Most published exoskeleton trials either focus narrowly on neuromotor outcomes in incomplete injury — where spontaneous recovery confounds attribution — or evaluate devices in acute rehabilitation settings where compensatory ambulation is not the primary goal. Studying complete (AIS-A) thoracic injury in a compensatory framework is more clinically honest: these users are unlikely to recover volitional gait, so the exoskeleton must justify itself as a durable assistive tool, not a neural retraining aid. The 11-of-13 completion rate across 60 sessions is encouraging for adherence, though the cohort remains small and monocentric, limiting generalizability. The absence of a control arm also makes it impossible to attribute physiological or quality-of-life changes to the exoskeleton specifically. Still, this multidimensional methodology — integrating engineering, clinical, and patient-experience metrics simultaneously — represents a maturing evaluative standard that future trials should replicate at scale.
